Pfizer presented Phase 3 data for its daily pill Litfulo (ritlecitinib) in vitiligo at the European Academy of Dermatology and Venereology annual meeting. The drug significantly improved skin pigment measures in two pivotal studies, paving the way for FDA and EMA submissions. If approved, it would compete with Incyte's topical treatment.
Separately, Pfizer reported mid-stage results for an eczema drug that cleared skin in a trial. Detailed results were competitive with Dupixent and Ebglyss, according to the report. However, one analyst argued the drug lacks differentiation amid an increasingly competitive landscape.
The two developments are unrelated beyond both being Pfizer dermatology programs. The vitiligo data are late-stage and regulatory submissions are planned; the eczema data are mid-stage and face a crowded market. No direct comparison between the two programs is provided in the sources.